登录 | 注册    关注公众号  
微信公众号
搜索
 > 【EphB4】

EphB4信息

英文名称:Ephrin type-B receptor 4
中文名称:B型肝配蛋白受体-4
靶点别称:Ephrin type-B receptor 4,MYK1,EPHB4,HTK,EPH Receptor B4,Tyrosine-Protein Kinase TYRO11,TYRO11,Tyrosine-Protein Kinase Receptor HTK,Soluble EPHB4 Variant 2,Soluble EPHB4 Variant 3,Ephrin Receptor EphB4,EC 2.7.10.1,HFASD,LMPHM7,CMAVM2,EC 2.7.10,EC:2.7.10.1,Soluble EPHB4 Variant 1,Receptor, EphB4,Hepatoma transmembrane kinase
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

EphB4产品列表

ACRO质量管理体系
 
评论(0)
 

EphB4 分子别名

EphB4,HTK,MYK1,TYRO11

EphB4 分子背景

Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.

EphB4 前沿进展

EphB4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
sEphB4-HSA Vas-01; sEphB4-HSA 临床二期 Vasgene 急性淋巴细胞白血病, 卡波济氏肉瘤, 非小细胞肺癌, 胆囊癌, 急性髓细胞样白血病, 费城染色体, 胆道癌, 前列腺癌, 肉瘤, 前体T-淋巴母细胞性淋巴瘤白血病, 慢性髓细胞白血病, 去势抵抗性前列腺肿瘤, 膀胱癌, 胰腺癌, 尿路上皮癌, 头颈部鳞状细胞癌, 肾细胞癌, 淋巴细胞性白血病, 实体瘤, 骨髓瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定